Huge revenue backlog. I think we'll trade in the current range until we get a next big news. Last quarter Biogen announced they only made $300k from Aduhelm. Does it mean prescribing doctors are hesitant about giving $50k drug to their patients because they are sceptical about the clinical trial result?? Or is it because of "bottleneck" issue like biogen's ceo described...? If Aduhelm sales continues to be underwhelming, I can see less money flowing into this field. We'll see
Ann: Business Update and September 2021 Quarter Cashflow, page-4
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.25 |
Change
0.015(1.21%) |
Mkt cap ! $214.2M | |||
| Open | High | Low | Value | Volume |
| $1.23 | $1.25 | $1.20 | $25.16K | 20.41K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 166 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 7948 | 3 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.25 |
Change
0.015 ( 2.79 %) |
||||
| Open | High | Low | Volume | ||
| $1.25 | $1.25 | $1.21 | 4780 | ||
| Last updated 15.58pm 14/05/2024 ? | |||||
| CGS (ASX) Chart |